INM
New deal, new identity
InMed Pharmaceuticals is doing the biotech equivalent of changing majors mid-semester. The company said it has signed a definitive all-stock merger agreement with private biotech Mentari Therapeutics, a move that drags InMed deeper into migraine prevention therapies.
Why migraine is the prize
Mentari isn’t just tossing spaghetti at the wall. Its lead programs are aimed at validated pathways — including anti-PACAP and a CGRP/PACAP bispecific — with the pitch that they could help the two-thirds of migraine patients who don’t get a great response from anti-CGRP treatments. That’s a pretty big “please solve this problem” sign hanging over the market.
The cash matters, too
Here’s the part that makes the deal feel a little less like biotech vaporware and a little more like an actual plan: Mentari also announced an oversubscribed US$290 million private placement. Management says that should fund operations through 2028, which is the kind of runway investors like to see when drug development can otherwise eat cash for breakfast.
What happens next
The companies say first-in-human regulatory filings for MT-001 and MT-002 are expected in mid-2026 and 1Q 2027, respectively. In other words, this isn’t a quick-fix headline pop — it’s a long biotech road trip with a very expensive map.
Big picture: InMed is betting that a migraine-focused pivot plus a fat private placement will give it a sharper story and a sturdier balance sheet. In biotech, that combo can be everything — or just the opening scene.